Walter E Kaufmann1,2, Sharon A Kidd3, Howard F Andrews4, Dejan B Budimirovic5, Amy Esler6, Barbara Haas-Givler7, Tracy Stackhouse8, Catharine Riley9, Georgina Peacock9, Stephanie L Sherman10, W Ted Brown11, Elizabeth Berry-Kravis12. 1. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts; wkaufmann@ggc.org. 2. Greenwood Genetic Center, Greenwood, South Carolina. 3. National Fragile X Foundation, Washington, District of Columbia. 4. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York. 5. Kennedy Krieger Institute, Baltimore, Maryland. 6. University of Minnesota, Minneapolis, Minnesota. 7. Geisinger Health System, Lewisburg, Pennsylvania. 8. Developmental FX, Denver, Colorado. 9. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia. 10. Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia. 11. New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York; and. 12. Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, Illinois.
Abstract
BACKGROUND AND OBJECTIVE: Individuals with fragile X syndrome (FXS) are frequently codiagnosed with autism spectrum disorder (ASD). Most of our current knowledge about ASD in FXS comes from family surveys and small studies. The objective of this study was to examine the impact of the ASD diagnosis in a large clinic-based FXS population to better inform the care of people with FXS. METHODS: The study employed a data set populated by data from individuals with FXS seen at specialty clinics across the country. The data were collected by clinicians at the patient visit and by parent report for nonclinical and behavioral outcomes from September 7, 2012 through August 31, 2014. Data analyses were performed by using χ2 tests for association, t tests, and multiple logistic regression to examine the association between clinical and other factors with ASD status. RESULTS: Half of the males and nearly 20% of females met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for current ASD. Relative to the FXS-only group, the FXS with ASD (FXS+ASD) group had a higher prevalence of seizures (20.7% vs 7.6%, P < .001), persistence of sleep problems later in childhood, increased behavior problems, especially aggressive/disruptive behavior, and higher use of α-agonists and antipsychotics. Behavioral services, including applied behavior analysis, appeared to be underused in children with FXS+ASD (only 26% and 16% in prekindergarten and school-age periods, respectively) relative to other populations with idiopathic ASD. CONCLUSIONS: These findings confirm among individuals with FXS an association of an ASD diagnosis with important cooccurring conditions and identify gaps between expected and observed treatments among individuals with FXS+ASD.
BACKGROUND AND OBJECTIVE: Individuals with fragile X syndrome (FXS) are frequently codiagnosed with autism spectrum disorder (ASD). Most of our current knowledge about ASD in FXS comes from family surveys and small studies. The objective of this study was to examine the impact of the ASD diagnosis in a large clinic-based FXS population to better inform the care of people with FXS. METHODS: The study employed a data set populated by data from individuals with FXS seen at specialty clinics across the country. The data were collected by clinicians at the patient visit and by parent report for nonclinical and behavioral outcomes from September 7, 2012 through August 31, 2014. Data analyses were performed by using χ2 tests for association, t tests, and multiple logistic regression to examine the association between clinical and other factors with ASD status. RESULTS: Half of the males and nearly 20% of females met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for current ASD. Relative to the FXS-only group, the FXS with ASD (FXS+ASD) group had a higher prevalence of seizures (20.7% vs 7.6%, P < .001), persistence of sleep problems later in childhood, increased behavior problems, especially aggressive/disruptive behavior, and higher use of α-agonists and antipsychotics. Behavioral services, including applied behavior analysis, appeared to be underused in children with FXS+ASD (only 26% and 16% in prekindergarten and school-age periods, respectively) relative to other populations with idiopathic ASD. CONCLUSIONS: These findings confirm among individuals with FXS an association of an ASD diagnosis with important cooccurring conditions and identify gaps between expected and observed treatments among individuals with FXS+ASD.
Authors: Donald B Bailey; Melissa Raspa; Ellen Bishop; Murrey Olmsted; Usha G Mallya; Elizabeth Berry-Kravis Journal: J Dev Behav Pediatr Date: 2012-01 Impact factor: 2.225
Authors: Christina Corsello; Vanessa Hus; Andrew Pickles; Susan Risi; Edwin H Cook; Bennett L Leventhal; Catherine Lord Journal: J Child Psychol Psychiatry Date: 2007-09 Impact factor: 8.982
Authors: Walter E Kaufmann; Ranon Cortell; Alice S M Kau; Irena Bukelis; Elaine Tierney; Robert M Gray; Christiane Cox; George T Capone; Pia Stanard Journal: Am J Med Genet A Date: 2004-09-01 Impact factor: 2.802
Authors: R Nick Hernandez; Rachel L Feinberg; Rebecca Vaurio; Natalie M Passanante; Richard E Thompson; Walter E Kaufmann Journal: Am J Med Genet A Date: 2009-06 Impact factor: 2.802
Authors: Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman Journal: Genome Med Date: 2012-12-21 Impact factor: 11.117
Authors: Gabriel Lázaro-Muñoz; Maya Sabatello; Laura Huckins; Holly Peay; Franziska Degenhardt; Bettina Meiser; Todd Lencz; Takahiro Soda; Anna Docherty; David Crepaz-Keay; Jehannine Austin; Roseann E Peterson; Lea K Davis Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2019-05-23 Impact factor: 3.568
Authors: Joseph D Buxbaum; David J Cutler; Mark J Daly; Bernie Devlin; Kathryn Roeder; Stephan J Sanders Journal: Am J Hum Genet Date: 2020-11-05 Impact factor: 11.025
Authors: Jessica L Armstrong; Austen B Casey; Tanishka S Saraf; Munmun Mukherjee; Raymond G Booth; Clinton E Canal Journal: ACS Pharmacol Transl Sci Date: 2020-02-21
Authors: Jessica Klusek; Carly Moser; Joseph Schmidt; Leonard Abbeduto; Jane E Roberts Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2019-08-16 Impact factor: 3.568
Authors: Pamela R Westmark; Alejandra Gutierrez; Aaron K Gholston; Taralyn M Wilmer; Cara J Westmark Journal: Neurochem Int Date: 2020-01-17 Impact factor: 3.921